Drug Profile
Candida antigen - Nielson Biosciences
Alternative Names: Candida albicans antigen - Nielson Biosciences; Candida albicans skin test antigen - Nielson Biosciences; CandinLatest Information Update: 07 Mar 2024
Price :
$50
*
At a glance
- Originator Nielsen BioSciences
- Developer Janssen Research & Development; Nielsen BioSciences
- Class Antigens; Diagnostic agents; Skin disorder therapies; Yeasts
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hypersensitivity
- Phase III Warts
Most Recent Events
- 07 Mar 2024 Maruho plans to commercialise CANDIN in Japan
- 06 Mar 2024 Phase-III clinical trials in Warts (In adolescents, In adults) in Japan, USA (unspecified route)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Allergy(Diagnosis, In adults) in Belgium (Intradermal, Injection)